September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
GATA-3 immunoreactivity in periocular sebaceous neoplasms
Author Affiliations & Notes
  • Austin Nakatsuka
    Transitional Program, University of Hawaii, Honolulu, Hawaii, United States
  • Kevin Guan
    Pathology, Queens Medical Center, Honolulu, Hawaii, United States
  • Pamela Tauchi-Nishi
    Pathology, Queens Medical Center, Honolulu, Hawaii, United States
  • Footnotes
    Commercial Relationships   Austin Nakatsuka, None; Kevin Guan, None; Pamela Tauchi-Nishi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2418. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Austin Nakatsuka, Kevin Guan, Pamela Tauchi-Nishi; GATA-3 immunoreactivity in periocular sebaceous neoplasms. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2418.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : GATA-3 binding protein is a transcription factor for gene regulation in cellular development, which has been associated with estrogen receptor (ER) expression and is frequently utilized as a sensitive and specific immunomarker for urothelial and breast carcinomas. Subsequent studies have demonstrated GATA-3 expression in other neoplasms, including cutaneous squamous cell carcinomas (SCC) and basal cell carcinoma (BCC), but not in melanomas. It has yet to be studied in sebaceous carcinomas (SC), poorly differentiated cancers which commonly involve the eyelid and may be difficult to distinguish from other periocular malignancies and metastases. Our study aims to determine the expression of GATA-3 in cutaneous sebaceous neoplasms.

Methods : Our database was searched from January 2003 to October 2015. We examined 77 periocular neoplasms including 20 sebaceous carcinomas (PSC), 19 sebaceous adenomas (PSA), 18 basal cell (PBCC) and 20 squamous cell carcinomas (PSCC). For comparison, we also studied 37 non-periocular sebaceous neoplasms including 19 carcinomas (NPSC) and 18 adenomas (NPSA). Histological sections were compiled into a tissue microarray and subjected to immunohistochemical (IHC) staining for GATA-3, as well as ER and PR (estrogen and progesterone receptors) and mammaglobin and GCDFP-15.

Results : IHC analysis revealed GATA-3 expression in nearly all neoplasm studied, including 100% of PSA, NPSA, and PBCC; 95% of PSC and NPSC; and 80% of PSCC. ER expression was noted in 32% of NPSC, 10% of PSC, 6% of PSA, and 5% of PSCCs. ER was negative in all NPSA and PBCC. No PR positivity was noted in any neoplasm. In addition, GCDFP-15 and mammaglobin staining was negative in all cases.

Conclusions : GATA-3 was expressed in the vast majority of periocular neoplasms, including PSC and PSA. Similar GATA-3 expression was noted in NPSC and NPSA. We conclude that GATA-3 is highly expressed in sebaceous carcinoma and adenoma. Most GATA-3 positive cases failed to correlate with ER positivity.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×